Journal of veterinary internal medicine · 2025
Evaluation of Hyperlipasemia and Clinical Signs in 106 Dogs After Hospitalization for Acute Pancreatitis: Results From a Combined Retrospective and Prospective Follow-Up Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kook Peter H
Аннотация
BACKGROUND: No data after hospitalization for acute pancreatitis (AP) in dogs comparing clinical signs to lipase results exists.
OBJECTIVES: Evaluate disease severity, lipase activity, and pancreatic lipase immunoreactivity (PLI) after hospitalization for suspected AP.
ANIMALS: One hundred and six client-owned dogs with a minimum of one re-check 2 weeks after hospitalization for AP.
METHODS: Combined retrospective and prospective study. Clinical signs graded using a clinical disease activity score (CDAS = CIBDAI complemented by abdominal pain) were compared to DGGR-lipase activity (LIPC Roche) and PLI (SpecPL) at 2 weeks (t2, n = 106) after discharge. Additional re-checks were available 6 weeks (t3, n = 56), 12 weeks (t4, n = 24), and 24 weeks (t5, n = 13) after discharge.
RESULTS: Lipase activity and PLI correlated strongly at all time points (rs 0.863-0.937, p < 0.0001). Discordant results in regard to published reference intervals (RI) were rare (2.8% at t2, 1.7% at t3, 4.2% at t4, 0% at t5) and seemed clinically irrelevant. Dogs with still elevated lipase activity and PLI at t2 (24/106.22.6%) and t3 (21/56.37.5%) were significantly older compared to dogs with lipase within RI. Weak and moderate correlation between CDAS and lipase activity/PLI was found only at t2 (rs 0.391, p = 0.0009; rs 0.279, p = 0.004) and t5 (rs 0.603, p = 0.032; rs 0.57 p = 0.045). Most dogs (79.2%) with still elevated lipase at t2 had no or minimal clinical signs (CDAS 0-3). The same applied to all later re-checks.
CONCLUSION AND CLINICAL IMPORTANCE: Both lipase assays did not differ when compared to clinical status. Most dogs with hyperlipasemia after hospitalization for AP have no or minimal clinical signs.
OBJECTIVES: Evaluate disease severity, lipase activity, and pancreatic lipase immunoreactivity (PLI) after hospitalization for suspected AP.
ANIMALS: One hundred and six client-owned dogs with a minimum of one re-check 2 weeks after hospitalization for AP.
METHODS: Combined retrospective and prospective study. Clinical signs graded using a clinical disease activity score (CDAS = CIBDAI complemented by abdominal pain) were compared to DGGR-lipase activity (LIPC Roche) and PLI (SpecPL) at 2 weeks (t2, n = 106) after discharge. Additional re-checks were available 6 weeks (t3, n = 56), 12 weeks (t4, n = 24), and 24 weeks (t5, n = 13) after discharge.
RESULTS: Lipase activity and PLI correlated strongly at all time points (rs 0.863-0.937, p < 0.0001). Discordant results in regard to published reference intervals (RI) were rare (2.8% at t2, 1.7% at t3, 4.2% at t4, 0% at t5) and seemed clinically irrelevant. Dogs with still elevated lipase activity and PLI at t2 (24/106.22.6%) and t3 (21/56.37.5%) were significantly older compared to dogs with lipase within RI. Weak and moderate correlation between CDAS and lipase activity/PLI was found only at t2 (rs 0.391, p = 0.0009; rs 0.279, p = 0.004) and t5 (rs 0.603, p = 0.032; rs 0.57 p = 0.045). Most dogs (79.2%) with still elevated lipase at t2 had no or minimal clinical signs (CDAS 0-3). The same applied to all later re-checks.
CONCLUSION AND CLINICAL IMPORTANCE: Both lipase assays did not differ when compared to clinical status. Most dogs with hyperlipasemia after hospitalization for AP have no or minimal clinical signs.